Diabetes, obesity & metabolism · 2026
A 52-Week Efficacy and Safety Study of Teneligliptin, as an Add-On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial (TERA305 Study).
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Moon Jun Sung, Han Kyung Ah, Kim Dong-Lim, Kim Sang Yong, Kim Soo-Kyung, Ku Bon Jeong, Lee Woo Je, Oh Tae Keun, Seo Ji A, Chang Sang-Ah, Lee Moon-Kyu, Ahn Kyu Jeung, Kim Chul Sik, Kim Tae Nyun, Cha Bong-Soo
Аннотация
AIMS: To evaluate the long-term efficacy and safety of teneligliptin add-on in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin.
MATERIALS AND METHODS: In this randomised, double-blind, phase 3 trial, 214 patients received teneligliptin 20 mg (n = 107) or placebo (n = 107) once daily for 24 weeks, in addition to metformin (≥ 1000 mg/day) and empagliflozin (25 mg/day). In a subsequent 28-week open-label extension, all patients received teneligliptin 20 mg/day. The primary endpoint was HbA1c change from baseline to week 24.
RESULTS: At week 24, the least squares mean (LSM) change in HbA1c from baseline was -0.70% ± 0.06% in the teneligliptin group and -0.03% ± 0.06% in the placebo group, with a placebo-adjusted LSM change of -0.67% (95% CI, -0.84 to -0.49; p < 0.0001), demonstrating the superiority of teneligliptin. A significant between-group difference was already evident at week 4 (placebo-adjusted LSM change, -0.36%; p < 0.0001). Significant reductions in fasting plasma glucose and glycated albumin and improvement in pancreatic β-cell function were observed at week 24. During the open-label extension, glycaemic improvements were maintained through week 52, although no concurrent randomised control was available beyond week 24. Placebo-group patients achieved a similar benefit after switching to teneligliptin. Safety outcomes did not differ between groups.
CONCLUSIONS: Adding teneligliptin to metformin and empagliflozin in patients with inadequately controlled T2DM significantly improved glycaemic control and β-cell function over 24 weeks and was well tolerated through 52 weeks.
TRAIL REGISTRATION: ClinicalTrials.gov Identifier: NCT05504226.
MATERIALS AND METHODS: In this randomised, double-blind, phase 3 trial, 214 patients received teneligliptin 20 mg (n = 107) or placebo (n = 107) once daily for 24 weeks, in addition to metformin (≥ 1000 mg/day) and empagliflozin (25 mg/day). In a subsequent 28-week open-label extension, all patients received teneligliptin 20 mg/day. The primary endpoint was HbA1c change from baseline to week 24.
RESULTS: At week 24, the least squares mean (LSM) change in HbA1c from baseline was -0.70% ± 0.06% in the teneligliptin group and -0.03% ± 0.06% in the placebo group, with a placebo-adjusted LSM change of -0.67% (95% CI, -0.84 to -0.49; p < 0.0001), demonstrating the superiority of teneligliptin. A significant between-group difference was already evident at week 4 (placebo-adjusted LSM change, -0.36%; p < 0.0001). Significant reductions in fasting plasma glucose and glycated albumin and improvement in pancreatic β-cell function were observed at week 24. During the open-label extension, glycaemic improvements were maintained through week 52, although no concurrent randomised control was available beyond week 24. Placebo-group patients achieved a similar benefit after switching to teneligliptin. Safety outcomes did not differ between groups.
CONCLUSIONS: Adding teneligliptin to metformin and empagliflozin in patients with inadequately controlled T2DM significantly improved glycaemic control and β-cell function over 24 weeks and was well tolerated through 52 weeks.
TRAIL REGISTRATION: ClinicalTrials.gov Identifier: NCT05504226.